Previous 10 | Next 10 |
The following slide deck was published by Syros Pharmaceuticals, Inc. in conjunction with their 2019 Q2 earnings Read more ...
Syros Pharmaceuticals (NASDAQ: SYRS ): Q2 GAAP EPS of -$0.47 misses by $0.05 . More news on: Syros Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Enrollment Initiated in Phase 2 Trial Cohort Evaluating SY-1425 and Azacitidine in Genomically Defined Patients with Relapsed or Refractory Acute Myeloid Leukemia Multiple Clinical Data Readouts Expected for SY-1425 and SY-1365 in 2019 and 2020 Management to Host Conference Call...
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, August 1, 2019 to report its second quarter 2019 financial results and provide ...
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced the appointment of Alice Tsang Shaw, M.D., Ph.D., to the Company’s Board of Directors. Dr. Shaw is a highly respected oncologis...
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities Life Sciences Conference. Details are as follo...
"During the flames of controversy, opinions, mass disputes, conflict, and world news, sometimes the most precious, refreshing, peaceful words to hear amidst all the chaos are simply and humbly 'I don't know .” ― Criss Jami Today we check back in on the progress of a small de...
SY-1365 Currently in Phase 1 Clinical Trial in Relapsed and Treatment-Resistant Ovarian and Breast Cancer Patients Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the online publication of a new manus...
Syros Pharmaceuticals, Inc. (SYRS) Q1 2019 Earnings Conference Call May 01, 2019 8:30 AM ET Company Participants Naomi Aoki - Vice President of Corporate Communications & Investor Relations Nancy Simonian - Chief Executive Officer Joe Ferra - Chief Financial Officer David R...
Syros Pharmaceuticals (NASDAQ: SYRS ): Q1 GAAP EPS of -$0.49 beats by $0.07 . More news on: Syros Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
Syros Pharmaceuticals Inc. Website:
-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected by Mid-4Q24 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in September 2024-- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NA...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its s...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...